ACE-031 vs GHRP-2.

ACE-031 (ramatercept) is not a peptide but a recombinant fusion protein that joins the extracellular domain of the human activin receptor type IIB (ActRIIB) to the Fc region of IgG1. Developed by Acceleron Pharma, it works as a ligand trap that soaks up myostatin and related TGF-beta-family proteins that normally restrain muscle growth. It was engineered as a candidate therapy for muscle-wasting conditions, most prominently Duchenne muscular dystrophy (DMD). Unlike most compounds grouped with muscle peptides, it genuinely reached human clinical trials before its development was stopped.

GHRP-2 (growth hormone-releasing peptide-2; international nonproprietary name pralmorelin; development codes KP-102/GPA-748) is a synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. It belongs to the "classical" growth hormone secretagogue (GHS) family pioneered by Cyril Bowers in the 1980s and is a synthetic agonist of the ghrelin receptor. Unlike GHRH, it is structurally unrelated to any hypothalamic releasing hormone and instead mimics the endogenous gut peptide ghrelin.

ActRIIB is a receptor through which myostatin (GDF-8), activins, and several other TGF-beta-superfamily ligands signal to limit skeletal muscle mass. By presenting a soluble decoy receptor, ACE-031 binds these ligands in the circulation and prevents them from activating ActRIIB on muscle, releasing the brake on muscle growth. Because the trap captures multiple ligands beyond myostatin, including some that act on blood vessels, it produces effects outside muscle as well. This mechanism was established in animal models and then probed directly in humans.

GHRP-2 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same Gq/11-coupled receptor targeted by ghrelin, expressed on anterior-pituitary somatotrophs and in the hypothalamus (including the arcuate nucleus). Receptor activation drives phospholipase C signaling, IP3/DAG generation, and intracellular calcium release, evoking pulsatile GH secretion. Because it acts through a pathway distinct from (and synergistic with) GHRH, GHRP-2 and GHRH together produce a markedly larger GH pulse than either alone. Its action on hypothalamic ghrelin-receptor circuits also explains its orexigenic (appetite-stimulating) effect and a degree of off-target activation of the corticotroph and lactotroph axes.

ACE-031 has genuine human data. Attie et al. reported a single ascending-dose study in healthy postmenopausal women in Muscle & Nerve (2013, PMID 23169607), observing increases in lean mass and biomarker changes consistent with myostatin inhibition. That was a phase 1 design: a small, single-administration, dose-escalating study in a narrowly selected healthy population, sponsored by the developer Acceleron Pharma, with imaging and biomarker endpoints rather than measures of function, and without the duration needed to detect anything that emerges over months. Campbell et al. published the randomized, placebo-controlled trial in ambulatory boys with DMD in Muscle & Nerve (2017, PMID 27462804), which showed trends toward preserved 6-minute-walk distance, higher lean mass and bone mineral density, and lower fat mass, but was stopped early. Because the trial was terminated before completing enrollment and follow-up, the walking-distance result remained a trend rather than a demonstrated benefit, the study lost the statistical power it had been designed with, and no confirmatory trial was ever run. Every efficacy statement about ACE-031 therefore rests on an interrupted study. This places ACE-031 well beyond the preclinical status of most muscle compounds, even though it never demonstrated confirmed clinical efficacy. The wider myostatin-pathway field has repeated the same pattern. Domagrozumab, an anti-myostatin antibody, failed its primary endpoint in Duchenne muscular dystrophy. Bimagrumab, an ActRII-blocking antibody, has produced consistent increases in lean mass without delivering the functional outcomes originally sought, and its cardiac safety has been examined separately in older adults (PMID 41873146). Increasing muscle mass has proven considerably easier than improving what patients can actually do. For ACE-031 specifically there is no chronic exposure data, no published long-term follow-up of the participants who were treated, no completed outcome trial, and no development activity after the early 2010s from which to draw further evidence.

Human pharmacology is well characterized for acute, single-dose use: controlled studies show GHRP-2 reliably triggers a robust GH pulse, and in healthy men it increased subjective hunger and food intake, confirming it behaves as a ghrelin mimetic (Laferrère et al., JCEM 2005). On the strength of acute diagnostic data it is approved in Japan as a single-dose GH-deficiency provocation test, where the GH response separates GH-sufficient from GH-deficient subjects. Critically, the long-term therapeutic program failed: development for treating GH-deficient children/pituitary dwarfism reached Phase II but was not brought to market, in part because the GH response to GHRP-2 is blunted in people with GH deficiency relative to healthy individuals. There are essentially no rigorous long-term human trials demonstrating benefit for body composition, muscle, anti-aging, or performance. Claims in those areas rest on mechanism and short-term hormone changes, not proven clinical outcomes.

The DMD program was halted in 2011 for safety reasons. Investigators observed dose-related, non-muscle vascular effects, specifically epistaxis (nosebleeds), gum bleeding, and telangiectasias (small dilated skin vessels), attributed to the trap's activity on additional TGF-beta-family ligands. The mechanistic explanation is that a soluble ActRIIB decoy does not bind myostatin alone: it also sequesters activins and bone morphogenetic proteins that help maintain vascular integrity, so the bleeding signal is a predictable consequence of the trap's breadth rather than an idiosyncratic reaction. These events appeared in children being treated for a serious progressive disease, the population most willing to accept risk for benefit, and they were still judged unacceptable. Acceleron and its partner Shire ended the collaboration and did not restart development. Short-term human exposure is documented, but the compound was discontinued precisely because of these off-target vascular signals, and long-term safety was never established. There is no chronic dosing data, no published long-term follow-up of the boys who were exposed, and no immunogenicity or reproductive toxicology in the public record. Later programs targeting the same pathway were deliberately engineered for narrower ligand selectivity in order to avoid this exact problem. Anything sold online under the ACE-031 name is an unapproved recombinant protein produced outside pharmaceutical manufacturing controls, where identity, glycosylation, aggregation state, and endotoxin content are all unverified, and aggregated Fc-fusion proteins carry their own immunogenicity risk. The monitoring a real trial would demand, including vascular and bleeding assessment, dermatologic examination, and anti-drug antibody testing, does not exist outside a clinical setting.

Documented acute effects in human studies include off-target stimulation of ACTH and cortisol and a transient rise in prolactin, a feature that distinguishes GHRP-2 from the more selective secretagogue ipamorelin (Arvat et al., Peptides 1997). As a ghrelin-receptor agonist it predictably stimulates appetite, and sustained GH/IGF-1 elevation carries the theoretical risks associated with the GH axis (insulin resistance, fluid retention, joint discomfort). The fundamental safety gap is that GHRP-2 has been studied chiefly as a one-time diagnostic agent; the consequences of repeated or chronic non-clinical use, including effects on the HPA axis, glucose metabolism, and any proliferative risk from prolonged IGF-1 elevation, have not been established in controlled long-term human trials. Material sold for "research" use is unregulated and may differ in identity, purity, or sterility from pharmaceutical-grade product.

ACE-031 was never approved by the FDA or any other regulator, and its clinical development was terminated in the early 2010s after the DMD trial was stopped for safety. It is not a marketed drug and is not legitimately available for human use. Any product sold online as ACE-031 is unapproved research-grade material.

Approved in Japan (marketed by Kaken Pharmaceutical as GHRP Kaken 100) solely as a single-dose diagnostic agent for assessing growth hormone deficiency, making it the only GHS ever granted national regulatory approval, and only for diagnosis, not therapy. It is not FDA-approved for any indication; in the United States and most jurisdictions it is investigational/research-use-only, and it is prohibited in sport under the WADA Prohibited List (S2, growth hormone secretagogues).